should not use clembuterol in combination treatment regimens Nikavir together with stavudine and, since these drugs are direct competitive mechanism of action, which may lead to a reduction activity.
In some patients treated with zidovudine together with phenytoin, there was a decrease in the blood concentration of the latter.
Some drugs, such as aspirin, codeine, morphine, indomethacin, ketoprofen, naproxen, oxazepam, lorazepam, cimetidine, clofibrate, dapsone, inosine pranobex, may affect metabolism by competitive inhibition of zidovudine and glyukuronirovaniya direct inhibition of microsomal liver enzymes. In appointing these drugs together with zidovudine should be considered the possibility of interaction.
Adriamycin, alpha-interferon, amphotericin-B, cotrimoxazole, vinblastine, vincristine, ganciclovir, dapsone, sulfadiazine and other sulfonamides used in conjunction with clembuterol, reinforce myelotoxicity.
Paracetamol – increases the incidence of neutropenia due to inhibition of metabolism of (both drugs glyukuroniruyutsya).
Radiation therapy – increases the risk of toxicity of zidovudine.
Clembuterol increases the concentration of fluconazole.
There synergistic effect with other drugs (drug) used against HIV (particularly lamivudine), on the replication of HIV in cell culture.
Nucleoside analogue ribavirin antagonizes the antiviral activity of zidovudine in vitro, so you should avoid the simultaneous use of these two drugs. Under the influence of probenecid reduces renal excretion of the glucuronide (and possibly zidovudine itself).
To avoid complications Zidovudine is used under medical supervision.
Patients should be warned that they should not be alone at a time to use other drugs. Irregular the drug can lead to development of resistance of the virus and reduce treatment efficiency.
Patients should be informed that zidovudine therapy does not reduce the risk of transmitting HIV to others through sexual contact or blood transfusion.
During treatment, carried out monitoring of peripheral blood: 1 every 2 weeks. during the first 3 months. therapy, then – 1 time per month.
Hematologic changes appear after 4-6 weeks. from the start of therapy (anemia and neutropenia often develops when used in high doses – 1500 mg / day in patients with reduced content of clembuterol, with untreated HIV infection (with reduced bone marrow reserve prior to treatment), neutropenia. anemia, vitamin B12 deficiency). By reducing Hb more than 25% reduction in the number of neutrophils or more than 50% compared to baseline – blood tests carried out more often. Patients receiving the drug may develop opportunistic infections and other. Complications of HIV infection, so they should remain under medical supervision.